Altre lingue HitGen Inc.

Azioni

688222

CNE1000040G3

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 30/04/2024			Variaz. 5gg	Var. 1 gen.
13,52 ^CNY	+1,27%		+4,16%	-9,81%

24/04	HitGen Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
23/02	HitGen Inc. riporta i risultati degli utili per l'intero anno conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23
Chengdu HitGen and the Structural Genomics Consortium have reached A Cooperation in the research and development of new drugs based on DEL technology Release time, 2023-09-28	29/09/23
HitGen Receives 10 Million Yuan in Government Subsidies	29/09/23
The Structural Genomics Consortium and HitGen Inc. Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery	28/09/23
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology	26/09/23
HitGen Inc.(XSSC:688222) added to S&P Global BMI Index	18/09/23
HitGen Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	22/08/23
Chengdu Hittech and Nested Therapeutics signed a new drug research and development service contract based on DEL technology	11/08/23
HitGen Inc. Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics, Inc	10/08/23
HitGen Inc. Launches A Newly Upgraded Version of OpenDELâ„¢, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research	26/06/23
HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23
Certain A Shares of HitGen Inc. are subject to a Lock-Up Agreement Ending on 16-APR-2023.	16/04/23
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	27/02/23
Tranche Update on HitGen Inc.'s Equity Buyback Plan announced on July 1, 2022.	30/12/22
HitGen Inc.'s Equity Buyback announced on July 1, 2022, has expired with 1,238,700 shares, representing 0.34% for CNY 20 million.	29/12/22
HitGen Inc. Announces Research Agreement with Nitrase Therapeutics, Inc. Focused on DNA-Encoded Library Based Drug Discovery	12/12/22
DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery	14/11/22
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue HitGen Inc.

Azioni

688222

CNE1000040G3

Altre lingue

Filtri